Bio-Optronics has announced the launch of their new Clinical Conductor CTMS product line. This update enables users to modify the software homepage to suit their needs and adapt with their workflows.
Bio-Optronics has announced the launch of its new Clinical Conductor CTMS product line. This update enables users to modify the software homepage to suit their needs and adapt with their workflows. These features include: drag and drop function, “pinning” studies and a study start-up wizard.
Read the full release here
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.